2004
Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction
Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E. Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction. Circulation 2004, 110: 1598-1604. PMID: 15353506, DOI: 10.1161/01.cir.0000142862.98817.1f.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdrenergic beta-AntagonistsAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinCohort StudiesCombined Modality TherapyCoronary AngiographyCoronary RestenosisFemaleHemorrhageHumansImmunoglobulin Fab FragmentsLife TablesMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsProportional Hazards ModelsPyridinesStentsStrokeTreatment OutcomeConceptsAcute myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsElderly patientsPercutaneous coronary interventionMajor bleedingYears of ageCoronary interventionClinical outcomesStent implantationMyocardial infarctionPlatelet glycoprotein IIb/IIIa inhibitorsDecile of ageMechanical reperfusion strategiesOne-year mortalityPrimary coronary interventionRate of strokeCoronary stent implantationImpact of ageRate of mortalityAbciximab administrationCADILLAC trialReperfusion modalityTarget revascularization
2003
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003, 108: 1316-1323. PMID: 12939213, DOI: 10.1161/01.cir.0000087601.45803.86.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyEndpoint DeterminationFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexStentsTreatment OutcomeConceptsComposite end pointTarget vessel revascularizationIschemia-driven target vessel revascularizationPrimary percutaneous coronary interventionAbciximab treatmentPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionCoronary interventionEnd pointPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsInfarct artery reocclusionPrespecified secondary analysisEvent-free survivalFactorial design trialLack of effectAbciximab useAngiographic substudyCADILLAC trialTVR ratesPrimary angioplastyPrimary stentingAngiographic outcomes
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting
2000
Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions
Mehran R, Dangas G, Mintz G, Lansky A, Pichard A, Satler L, Kent K, Stone G, Leon M. Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. Circulation 2000, 101: 604-610. PMID: 10673251, DOI: 10.1161/01.cir.101.6.604.Peer-Reviewed Original ResearchConceptsCK-MB elevationAtherosclerotic plaque burdenPreintervention intravascular ultrasoundPlaque burdenTimes upper limitIntravascular ultrasoundCoronary interventionSerum creatine kinase MB fractionPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsReference segmentsFinal minimal lumen diameterLesion site plaque burdenIIb/IIIa inhibitorsCreatine kinase MB fractionAngiographic lesion morphologyDe novo lesionsNative coronary lesionsPercutaneous coronary interventionMinimal lumen diameterDiffuse atherosclerotic diseaseCatheter-based interventionsCross-sectional narrowingAtheroablative techniquesLate mortality
1998
Heparin dosing in patients undergoing coronary intervention
Popma J, Prpic R, Lansky A, Piana R. Heparin dosing in patients undergoing coronary intervention. The American Journal Of Cardiology 1998, 82: 19p-24p. PMID: 9809888, DOI: 10.1016/s0002-9149(98)00759-0.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsCoronary interventionHeparin therapyHemochron devicePlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsUncomplicated coronary interventionsWeight-adjusted heparinAntithrombotic regimenHemoTec deviceHeparin bolusHeparin dosingSufficient heparinHeparin administrationConventional heparinUnfractionated heparinSignificant thrombocytopeniaPatientsACT levelsHeparinLonger durationTarget ACTInterventionAnticoagulation